ReviewFrontiers in oncology2015
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy.
Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.Journal for immunotherapy of cancer · 2021Trial
- It Looks Like a Zebra but Is Not: [Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.Frontiers in pharmacology · 2021Review
- miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.PloS one · 2020Article
- Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- Review
- Article
- A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.Human vaccines & immunotherapeutics · 2017Article
- Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.Experimental and therapeutic medicine · 2017Article
- Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.Clinical and translational radiation oncology · 2017Review
- New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.OncoTargets and therapy · 2017Review
- Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.Melanoma management · 2016Article
- Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8Human vaccines & immunotherapeutics · 2016Article
- Update on clinical research and state of the art management of patients with advanced sarcomas and GIST.ESMO open · 2016Review
- Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms.mAbs · 2016Article
- Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effectsOncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After Coley's observation in 1891 of tumor regression in a patient who developed a postoperative infection, the field of immunotherapy is finally reborn. Avoiding immune destruction is now considered a hallmark of cancer, and the immunotherapy arena has exploded with the recent advances demonstrating an improvement in survival and a durability of response in patients with different cancer types, which translates into improved overall survival benefit. Here, we provide an overview of the main immune-oncology treatment strategies that, either alone or in combination, are undergoing clinical development. Namely, we will refer to those immunotherapeutic strategies that include adoptive transfer of ex vivo activated T cells, immunomodulatory monoclonal antibodies, and cancer vaccines. Our major focus will be to describe these approaches in melanoma, a cancer type transformed by immunotherapy into a potentially curable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.